- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02682394
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
February 12, 2016 updated by: Soroka University Medical Center
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients with Pancreatic Cancer
Study Overview
Status
Unknown
Conditions
Detailed Description
- Finding patients with pancreatic cancer (in all stages), before any treatment.
- Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver.
- Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease.
- Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.
Study Type
Observational
Enrollment (Anticipated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beer Sheva, Israel
- Recruiting
- Soroka University Medical Center
-
Contact:
- Vladimir Borodetsky, MD
- Phone Number: +972547428882
- Email: zivova1982@gmail.com
-
Contact:
- Irina Lazerev, MD
- Phone Number: +972526226458
- Email: irinalaz@clalit.org.il
-
Principal Investigator:
- Alla Khashper, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
30 patients diagnosed with any pancreatic cancer, in any stage, before treatment.
Description
Inclusion Criteria:
- patients diagnosed with any pancreatic cancer, in any stage, before treatment.
- >18 y.o
Exclusion Criteria:
- claustrophobia
- GFR<30
- patients with non mri compatible devices (e.g. orthopaedic external fixation system)
- After chemotherapy treatment or surgical procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area.
Time Frame: at 24 hours before chemotherapy starting
|
measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting.
|
at 24 hours before chemotherapy starting
|
|
Blood levels of free DNA
Time Frame: The blood sample taken 15 minutes prior to MRI study, at time of IV access.
|
Correlation of free DNA level and metastatic spread.
|
The blood sample taken 15 minutes prior to MRI study, at time of IV access.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alla Khashper, MD, Soroka University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Anticipated)
September 1, 2017
Study Completion (Anticipated)
October 1, 2017
Study Registration Dates
First Submitted
December 28, 2015
First Submitted That Met QC Criteria
February 12, 2016
First Posted (Estimate)
February 15, 2016
Study Record Updates
Last Update Posted (Estimate)
February 15, 2016
Last Update Submitted That Met QC Criteria
February 12, 2016
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOR0216-15CTIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.